ID28026A - COMPOUNDS 1,2,3,4-TETRAHIDROKUINOLINA-SUBSTITUSI-4-CARBOXSIAMINO-2 AS CETP RESIDENTS - Google Patents

COMPOUNDS 1,2,3,4-TETRAHIDROKUINOLINA-SUBSTITUSI-4-CARBOXSIAMINO-2 AS CETP RESIDENTS

Info

Publication number
ID28026A
ID28026A IDW20010622A ID20010622A ID28026A ID 28026 A ID28026 A ID 28026A ID W20010622 A IDW20010622 A ID W20010622A ID 20010622 A ID20010622 A ID 20010622A ID 28026 A ID28026 A ID 28026A
Authority
ID
Indonesia
Prior art keywords
tetrahidrokuinolina
substitusi
carboxsiamino
cetp
residents
Prior art date
Application number
IDW20010622A
Other languages
Indonesian (id)
Inventor
Michael Paul Deninno
George Tetteh Magnus Aryitey
Roger Benjamin Ruggeri
Ronald Thure Wester
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID28026A publication Critical patent/ID28026A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
IDW20010622A 1998-09-17 1999-09-10 COMPOUNDS 1,2,3,4-TETRAHIDROKUINOLINA-SUBSTITUSI-4-CARBOXSIAMINO-2 AS CETP RESIDENTS ID28026A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10086098P 1998-09-17 1998-09-17

Publications (1)

Publication Number Publication Date
ID28026A true ID28026A (en) 2001-05-03

Family

ID=22281914

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010622A ID28026A (en) 1998-09-17 1999-09-10 COMPOUNDS 1,2,3,4-TETRAHIDROKUINOLINA-SUBSTITUSI-4-CARBOXSIAMINO-2 AS CETP RESIDENTS

Country Status (47)

Country Link
US (4) US6197786B1 (en)
EP (1) EP1114031B1 (en)
JP (3) JP3626685B2 (en)
KR (1) KR100428330B1 (en)
CN (1) CN1331858C (en)
AP (1) AP1346A (en)
AR (1) AR021481A1 (en)
AT (1) ATE297898T1 (en)
AU (1) AU752566B2 (en)
BG (1) BG65125B1 (en)
BR (1) BR9913810A (en)
CA (1) CA2344350C (en)
CO (1) CO5370678A1 (en)
CR (1) CR6310A (en)
CU (1) CU23082A3 (en)
CZ (1) CZ2001955A3 (en)
DE (1) DE69925845T2 (en)
DK (1) DK1114031T3 (en)
DZ (1) DZ2890A1 (en)
EA (1) EA004674B1 (en)
EE (1) EE200100166A (en)
ES (1) ES2243069T3 (en)
GE (1) GEP20033051B (en)
GT (1) GT199900150A (en)
HK (1) HK1040243A1 (en)
HN (1) HN1999000154A (en)
HR (1) HRP20010201A2 (en)
HU (1) HUP0103506A3 (en)
ID (1) ID28026A (en)
IL (3) IL141505A0 (en)
IS (1) IS5859A (en)
MA (1) MA26688A1 (en)
MY (1) MY130670A (en)
NO (1) NO318830B1 (en)
NZ (1) NZ509840A (en)
OA (1) OA11650A (en)
PA (1) PA8481401A1 (en)
PE (1) PE20001069A1 (en)
PL (1) PL347099A1 (en)
PT (1) PT1114031E (en)
SK (1) SK3542001A3 (en)
TN (1) TNSN99171A1 (en)
TR (1) TR200100768T2 (en)
TW (1) TWI242007B (en)
UA (1) UA68390C2 (en)
WO (1) WO2000017164A1 (en)
YU (1) YU16501A (en)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220909A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040230559A1 (en) * 1999-08-09 2004-11-18 Mark Newman Information processing device and information processing method
HN2000000203A (en) * 1999-11-30 2001-06-13 Pfizer Prod Inc PROCEDURE FOR OBTAINING 1,2,3,4-TETRAHYDROQUINOLINS 4-CARBOXYAMIN-2-SUBSTITUTED.
CO5271716A1 (en) * 1999-11-30 2003-04-30 Pfizer Prod Inc CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
JP2004506008A (en) * 2000-08-15 2004-02-26 ファイザー・プロダクツ・インク Therapeutic combination
EP1325914A4 (en) 2000-09-14 2004-11-17 Kaken Pharma Co Ltd tetrahydroquinoline
DK1383734T3 (en) 2001-04-30 2006-05-15 Pfizer Prod Inc Compounds useful as intermediates for 4-aminoquinoline derivatives
HUP0400263A2 (en) * 2001-06-21 2005-03-29 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
ES2333645T3 (en) * 2001-06-22 2010-02-25 Bend Research, Inc. PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF MEDICINES AND NEUTRAL POLYMERS.
JP2004534811A (en) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク Pharmaceutical composition comprising a polymer and drug assembly
DE60220049T2 (en) 2001-06-22 2007-08-30 Pfizer Products Inc., Groton A pharmaceutical composition comprising a solid dispersion of a sparingly water soluble drug and a solubility enhancing polymer
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CZ20033456A3 (en) * 2001-06-22 2004-07-14 Pfizer Products Inc. Pharmaceutical compositions comprising adsorbates of amorphous drug
GT200200170A (en) 2001-09-28 2003-05-23 PREPARATION OF INHIBITOR OF CETP ANHIDRO
MXPA04005864A (en) * 2001-12-19 2004-10-29 Atherogenics Inc Chalcone derivatives and their use to treat diseases.
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
AR038375A1 (en) 2002-02-01 2005-01-12 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF THE PROTEIN OF TRANSFER OF ESTERES DE COLESTERILO
MXPA04007433A (en) 2002-02-01 2004-10-11 Pfizer Prod Inc Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus.
MXPA04007428A (en) * 2002-02-01 2004-10-11 Pfizer Prod Inc Immediate release dosage forms containing solid drug dispersions.
JP2005522424A (en) * 2002-02-01 2005-07-28 ファイザー・プロダクツ・インク Controlled release drug dosage forms of cholesteryl ester transfer protein inhibitors
JP2005523262A (en) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming substances
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
ES2277142T3 (en) 2002-08-30 2007-07-01 Japan Tobacco Inc. DIBENCILAMINE COMPOSITE AND ITS MEDICINAL USE.
MXPA05003456A (en) * 2002-10-04 2005-07-05 Millennium Pharm Inc Pgd2 receptor antagonists for the treatment of inflammatory diseases.
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
CA2500083A1 (en) * 2002-10-21 2004-04-29 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
AU2003303239A1 (en) * 2002-12-19 2004-07-14 Atherogenics, Inc. Process of making chalcone derivatives
CA2509688A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE407670T1 (en) * 2002-12-20 2008-09-15 Pfizer Prod Inc DOSAGE FORM CONTAINING A CETP INHIBITOR AND A HMG-COA REDUCTASE INHIBITOR
WO2004072046A2 (en) * 2003-02-12 2004-08-26 Carex S.A. Quinoline derivatives and their use for modulation of lxr activity
WO2004072042A2 (en) * 2003-02-12 2004-08-26 Carex S.A. Quinoline derivative and their use for modulation of lxr activity
CN1777419B (en) * 2003-03-17 2010-04-28 日本烟草产业株式会社 Pharmaceutical compositions of CETP inhibitors
CA2519458A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
PL1603553T3 (en) 2003-03-17 2012-04-30 Japan Tobacco Inc Pharmaceutical compositions of cetp inhibitors
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
TWI494102B (en) * 2003-05-02 2015-08-01 Japan Tobacco Inc Combination comprising s-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino)phenyl)2-methylpropanethioate and an hmg coa reductase inhibitor
NZ577031A (en) * 2003-05-30 2010-09-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-CO inhibitors
ATE540671T1 (en) * 2003-08-04 2012-01-15 Bend Res Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DRUG ADSORBATES AND LIPOPHILIC MICROPHASE-FORMING MATERIALS
MXPA06001506A (en) * 2003-08-04 2006-05-15 Pfizer Prod Inc Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors.
CL2004001884A1 (en) 2003-08-04 2005-06-03 Pfizer Prod Inc DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS.
WO2005030185A2 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
WO2005033082A2 (en) * 2003-09-30 2005-04-14 Pfizer Products Inc. Cetp inhibitors and metabolites thereof
BRPI0414186A (en) * 2003-10-08 2006-10-31 Lilly Co Eli compounds, methods of antagonizing cetp activity, treating or preventing a disease, lowering plasma ldl cholesterol in a mammal, treating and / or preventing pathological sequelae, pharmaceutical formulation, and use of a compound
JP4839221B2 (en) * 2003-11-07 2011-12-21 ジェイ ジェイ ファーマ，インコーポレイテッド Combination therapy combination to increase HDL
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
ATE433984T1 (en) 2004-03-26 2009-07-15 Lilly Co Eli COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA
US7923043B2 (en) * 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
UA90269C2 (en) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Tetrahydroquinoline derivatives and a process for preparing the same
MY139887A (en) * 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
CA2570688A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
EP1809759B1 (en) 2004-10-06 2013-09-11 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
MX2007005129A (en) 2004-10-27 2007-09-11 Daiichi Sankyo Co Ltd Benzene compound having 2 or more substituents.
MX2007005137A (en) * 2004-11-23 2007-06-22 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia.
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
EP2548894A1 (en) 2005-02-03 2013-01-23 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
AU2006216713A1 (en) * 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (en) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Method for inhibiting lipid absorption and lipid absorption inhibitor
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
GT200600381A (en) 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
JP4681526B2 (en) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 Pharmaceutical composition
WO2007054896A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
UY30117A1 (en) 2006-01-31 2007-06-29 Tanabe Seiyaku Co AMIS TRISUSTITUDED COMPOUND
PE20071025A1 (en) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp TRISUSTITUTED AMINE COMPOUND
TW200744583A (en) * 2006-03-14 2007-12-16 Ranbaxy Lab Ltd Statin stabilizing dosage formulations
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
US20100029716A1 (en) * 2006-04-10 2010-02-04 Concert Pharmaceuticals, Inc. Novel 1,2,3,4- tetrahydroquinoline derivatives
EP2049102A4 (en) * 2006-07-14 2010-12-22 Ranbaxy Lab Ltd Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
ITMI20062254A1 (en) * 2006-11-24 2008-05-25 Acraf USE OF A METHOXY-ALCANOIC ACID OF THE INZOL TO PREPARE A PHARMACEUTICAL COMPOSITION
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
AR065670A1 (en) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTIHIPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
WO2008115442A1 (en) 2007-03-16 2008-09-25 Concert Pharmceuticals, Inc. Inhibitors of cholesterol ester transfer protein
NZ580777A (en) 2007-04-13 2011-05-27 Kowa Co Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound
JP4846769B2 (en) * 2007-07-30 2011-12-28 田辺三菱製薬株式会社 Pharmaceutical composition
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
JP5659224B2 (en) 2009-05-15 2015-01-28 ノバルティス アーゲー Arylpyridines as aldosterone synthase inhibitors
US8455522B2 (en) 2009-05-15 2013-06-04 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
MX2011012628A (en) 2009-05-28 2011-12-14 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors.
ES2582395T3 (en) 2009-05-28 2016-09-12 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
TWI450896B (en) * 2009-06-30 2014-09-01 Lilly Co Eli Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
CN102712589B (en) 2009-11-17 2015-05-13 诺华股份有限公司 Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
CN102666535B (en) 2009-11-30 2015-02-25 诺华股份有限公司 Imidazole derivatives as aldosterone synthase inhibitors
PE20121743A1 (en) 2010-02-19 2012-12-22 Boehringer Ingelheim Int TRICYCLIC PYRIDINE DERIVATIVES, DRUGS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION
EP2571860A1 (en) 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl benzoylamides
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
EP2668507B1 (en) 2011-01-26 2017-08-23 INSERM - Institut National de la Santé et de la Recherche Médicale Method for assessing a subject's risk of having a cardiovascular disease.
JP2014506887A (en) 2011-02-17 2014-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
CA2828343A1 (en) 2011-03-04 2012-09-13 The Scripps Research Institute Edn3-like peptides and uses thereof
TWI537262B (en) * 2011-08-17 2016-06-11 美國禮來大藥廠 Novel 1,2,3,4-tetrahydroquinoline derivatives for the treatment of diabetes
WO2013024130A1 (en) 2011-08-17 2013-02-21 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
JPWO2013080999A1 (en) 2011-11-29 2015-04-27 興和株式会社 NPC1L1 and / or LIPG mRNA expression inhibitor and obesity prevention and / or treatment agent
UY35144A (en) 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
JP6295277B2 (en) 2013-02-14 2018-03-14 ノバルティス アーゲー Substituted bisphenylbutanoic acid phosphonic acid derivatives as NEP (neutral endopeptidase) inhibitors
BR112015026513A2 (en) 2013-04-17 2017-07-25 Pfizer n-piperidin-3-ylbenzamide derivatives to treat cardiovascular disease
TW201536814A (en) 2013-07-25 2015-10-01 Novartis Ag Synthetic cyclic polypeptides for the treatment of heart failure
PE20160991A1 (en) 2013-07-25 2016-10-15 Novartis Ag BIOCONJUGATES OF SYNTHETIC APELLIN POLYPEPTIDES
JP6854752B2 (en) 2014-07-30 2021-04-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Genetic markers for predicting responsiveness to treatment with HDL-elevating agents or HDL mimetics
LT3180314T (en) * 2014-08-12 2022-11-10 Newamsterdam Pharma B.V. METHOD OF PREPARATION OF SYNTHETIC INTERMEDIATE COMPOUNDS FOR THE PRODUCTION OF TETRAHYDROQUINOLINE DERIVATIVES
MX389591B (en) 2014-08-29 2025-03-20 Tes Pharma S R L Inhibitors of î±-amino-î²-carboxymuconic acid semialdehyde decarboxylase
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2016116842A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
JOP20190086A1 (en) 2016-10-21 2019-04-18 Novartis Ag Naphthyridinone derivatives and their use in the treatment of arrhythmia
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
RS66416B1 (en) 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS A PCSK9 INHIBITOR AND METHODS OF ITS APPLICATION
AR127698A1 (en) 2021-11-23 2024-02-21 Novartis Ag NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
KR20260015867A (en) 2023-05-24 2026-02-03 노파르티스 아게 Naphthyridinone derivatives for the treatment of diseases or disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231402A (en) * 1985-04-02 1993-07-27 Telefunken Systemtechnik Gmbh Method for detecting and classifying helicopters
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) * 1990-06-18 1994-01-04 E. R. Squibb & Sons, Inc. Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
JPH0676403B2 (en) 1991-01-18 1994-09-28 エスエス製薬株式会社 Novel benzo [5,6 cyclohepta [1,2-b pyridine derivative and antiallergic agent containing the same]
US5288725A (en) 1992-10-15 1994-02-22 Merck & Co., Inc. Pyrroloquinoline Bradykinin antagonist
DE19627431A1 (en) 1996-07-08 1998-01-15 Bayer Ag Heterocyclically fused pyridines
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6170342B1 (en) * 1997-05-19 2001-01-09 Particle Science Spiral sampler
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (en) * 1998-09-17 1999-09-06 1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED.
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
DK1383734T3 (en) * 2001-04-30 2006-05-15 Pfizer Prod Inc Compounds useful as intermediates for 4-aminoquinoline derivatives

Also Published As

Publication number Publication date
NO20011350D0 (en) 2001-03-16
NO318830B1 (en) 2005-05-09
US6906082B2 (en) 2005-06-14
DK1114031T3 (en) 2005-09-12
HRP20010201A2 (en) 2002-04-30
HN1999000154A (en) 2000-01-12
AP2001002101A0 (en) 2001-03-31
TNSN99171A1 (en) 2005-11-10
UA68390C2 (en) 2004-08-16
NZ509840A (en) 2002-11-26
US20040092550A1 (en) 2004-05-13
EP1114031A1 (en) 2001-07-11
CN1331858C (en) 2007-08-15
GT199900150A (en) 2001-03-03
YU16501A (en) 2004-05-12
BG65125B1 (en) 2007-03-30
CO5370678A1 (en) 2004-02-27
US6586448B1 (en) 2003-07-01
WO2000017164A1 (en) 2000-03-30
NO20011350L (en) 2001-05-09
GEP20033051B (en) 2003-08-25
PA8481401A1 (en) 2002-02-21
BR9913810A (en) 2001-06-19
US20050245570A1 (en) 2005-11-03
DE69925845T2 (en) 2006-05-18
EP1114031B1 (en) 2005-06-15
CZ2001955A3 (en) 2001-12-12
JP2006188542A (en) 2006-07-20
EA200100202A1 (en) 2001-10-22
JP3626685B2 (en) 2005-03-09
CU23082A3 (en) 2005-08-17
IL141505A0 (en) 2002-03-10
IL141505A (en) 2007-02-11
JP2002526475A (en) 2002-08-20
DZ2890A1 (en) 2003-12-15
ES2243069T3 (en) 2005-11-16
AU752566B2 (en) 2002-09-19
MA26688A1 (en) 2004-12-20
ATE297898T1 (en) 2005-07-15
JP2004339239A (en) 2004-12-02
PE20001069A1 (en) 2000-10-19
KR20010085813A (en) 2001-09-07
PL347099A1 (en) 2002-03-25
HK1040243A1 (en) 2002-05-31
AR021481A1 (en) 2002-07-24
CA2344350A1 (en) 2000-03-30
DE69925845D1 (en) 2005-07-21
HUP0103506A3 (en) 2002-11-28
CN1318058A (en) 2001-10-17
KR100428330B1 (en) 2004-04-28
BG105428A (en) 2002-01-31
OA11650A (en) 2004-12-07
TWI242007B (en) 2005-10-21
EA004674B1 (en) 2004-06-24
PT1114031E (en) 2005-09-30
AP1346A (en) 2004-12-15
EE200100166A (en) 2002-06-17
SK3542001A3 (en) 2002-06-04
HUP0103506A2 (en) 2002-01-28
AU5440199A (en) 2000-04-10
MY130670A (en) 2007-07-31
IL173393A0 (en) 2006-06-11
TR200100768T2 (en) 2001-07-23
US6197786B1 (en) 2001-03-06
IS5859A (en) 2001-02-23
CA2344350C (en) 2007-01-02
CR6310A (en) 2003-11-25

Similar Documents

Publication Publication Date Title
ID28026A (en) COMPOUNDS 1,2,3,4-TETRAHIDROKUINOLINA-SUBSTITUSI-4-CARBOXSIAMINO-2 AS CETP RESIDENTS
ATE277906T1 (en) 4-CARBOXAMINO-2-METHYL-1,2,3,4-TETRAHYDROCHINOLINES AS CETP INHIBITORS
ID29241A (en) TERANELASI KINOLIN DISTRICTS-1,2
DE69933287D1 (en) 12,13-MODIFIED EPOTHILON DERIVATIVES
FI4209U1 (en) New compounds
ID26909A (en) DOWN 1,3,4-OKSADIAZOLON
DE60025958D1 (en) 14,15-BETA-METHYLENE SUBSTITUTED ANDROGENE
DK1149106T3 (en) 4,5-azolo-oxindoles
FI980824A0 (en) Behandling av ett datameddelande i ett naetelement i ett datakommunikationsnaet
EP1156040A4 (en) 2,4-dioxo-5-ARYLIDENIMINO-1,3-PYRIMIDINE
FI980176A0 (en) Foerfarande Foer avspelning av ett meddelande i en vaexel Foer ett telekommunikationsnaet
ID26368A (en) DECREASED 2, HYDROMICIN DEXY
NO980270L (en) Trekka scheme
DE59909590D1 (en) AZIDFREE, GAS-CREATING COMPOSITION
DE69908923D1 (en) 1,3,4-THIADIAZOLYLAZO DYE-INK COMPOSITIONS
DE60017150D1 (en) 1,4,5,6-Tetra-Hydropropylidene-Derivatives as VITRONECTIN-INHIBITORS
FI980405A0 (en) Industriellt, kontinuerligt foerfarande Foer framstaellning av "gravkalk"
SE9801397D0 (en) Novel compounds
SE9804494D0 (en) Novel compounds
SE9804493D0 (en) Novel compounds
SE9803669D0 (en) Novel compounds
SE9800458D0 (en) Novel compounds
SE9801989D0 (en) Novel compounds
SE9804211D0 (en) Novel compounds
NO981550D0 (en) Trekka scheme